Shawn Magee, MD
Pulmonary Disease · Topeka, KSNPI 1831138460
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $396 and has fallen 91.7% since, to $33 in 2023. That places this record below the midpoint for pulmonary disease clinicians in KS, where the typical reported total is $1,991.
Across 38 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$92
- GSK$81
- AstraZeneca$55
- Jazz Pharmaceuticals Inc.$46
- Philips North America LLC$44
- Boehringer Ingelheim$44
- plus $283 from 15 others
Across 1 payment — averaging $10,303 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$10K
What the payments were for
- Food & beverage$63098%
- Education$152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 1 | $92 |
| GSK | 6 | $81 |
| AstraZeneca | 3 | $55 |
| Jazz Pharmaceuticals Inc. | 3 | $46 |
| Philips North America LLC | 3 | $44 |
| Boehringer Ingelheim | 3 | $44 |
| Mylan Specialty L.p. | 3 | $36 |
| 3b Medical, Inc. | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Shire North American Group Inc | 2 | $23 |
| Novo Nordisk | 1 | $20 |
| Harmony Biosciences LLC | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $15 |
| CSL Behring | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Amgen | 1 | $13 |
| Novartis | 1 | $12 |
| Merck | 1 | $11 |
| Electromed, Inc. | 1 | $11 |
How this compares
$645 in reported general payments places this provider in the 30th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 12 | $153,730 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $78,354 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $55,521 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $17,735 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $16,065 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $7,855 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $4,893 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $3,598 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 76 | $2,288 |
| Montelukast Sodium | 24 | $243 |
| Prednisone | 23 | $105 |
| Fluticasone Propionate | 13 | $89 |
| Azithromycin | 11 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $81 | $89,321132 claims |
| Boehringer IngelheimStiolto Respimat | $44 | $7,85513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Topeka
- Hassan TahaTopeka$7K
- Miguel Tsukayama OdaTopeka$6K
- Vimalkumar PatelTopeka$5K
- Abhishek ChakrabortiTopeka$4K
- Amanda GudgellTopeka$856
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Abdel-Ghanie Abu-SamraWichita$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.